<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1995-4484-2020-340-343</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-2903</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ДИСКУССИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>DISCUSSION</subject></subj-group></article-categories><title-group><article-title>Вызывают ли нестероидные противовоспалительные препараты специфические осложнения при коронавирусной инфекции COVID-19?</article-title><trans-title-group xml:lang="en"><trans-title>DO NSAIDS CAUSE SPECIFIC COMPLICATIONS IN COVID-19 CORONAVIRUS INFECTION?</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1391-0711</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каратеев</surname><given-names>А. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Karateev</surname><given-names>A. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Андрей Евгеньевич Каратеев </p><p>115522, Москва, Каширское шоссе, 34А </p></bio><bio xml:lang="en"><p>Andrey Karateev </p><p>34A, Kashirskoe Shosse, Moscow 115522</p></bio><email xlink:type="simple">aekarat@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1598-8360</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Насонов</surname><given-names>Е. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Nasonov</surname><given-names>E. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А ;</p><p>119991 Москва, ул. Трубецкая, 8, стр. 2 </p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522;</p><p>8, Trubetskaya St., Build. 2, Moscow 119991 </p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6068-3080</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лила</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Lila</surname><given-names>A. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А;</p><p>125993, Москва, ул. Баррикадная, 2/1, стр. 1 </p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522;</p><p>2/1, Barrikadnaya St., Build. 1, Moscow 125993 </p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГAОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>24</day><month>06</month><year>2020</year></pub-date><volume>58</volume><issue>3</issue><fpage>340</fpage><lpage>343</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Каратеев А.Е., Насонов Е.Л., Лила А.М., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Каратеев А.Е., Насонов Е.Л., Лила А.М.</copyright-holder><copyright-holder xml:lang="en">Karateev A.E., Nasonov E.L., Lila A.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/2903">https://rsp.mediar-press.net/rsp/article/view/2903</self-uri><abstract><p>В настоящее время нет четких данных, свидетельствующих о риске специфических осложнений при использовании препаратов из группы нестероидных противовоспалительных препаратов (НПВП), и в частности ибупрофена, при инфекции COVID-19. Также нет четких клинических данных, что прием НПВП повышает риск инфицирования коронавирусом COVID-19. Тем не менее при использовании НПВП у пациентов с острыми респираторными вирусными заболеваниями следует помнить о возможности развития класс-специфических осложнений со стороны желудочно-кишечного тракта, кардиоваскулярной системы и почек. Этот риск представляется достаточно серьезным у пожилых пациентов со множественными коморбидными заболеваниями. Кроме того, следует учитывать, что прием НПВП и парацетамола может маскировать важные симптомы инфекции COVID-19 (в частности, лихорадку) и удлинять сроки постановки правильного диагноза.</p></abstract><trans-abstract xml:lang="en"><p>Currently, there is no clear data indicating the risk of specific complications when using non-steroidal anti-inflammatory drugs (NSAIDs), and in particular ibuprofen, for COVID-19 infection. There is also no clear clinical evidence that taking NSAIDs increases the risk of COVID-19 infection. However, when using NSAIDs in patients with acute respiratory viral diseases, keep in mind the possibility of class-specific complications from the gastrointestinal tract, cardiovascular system and kidneys. This risk is quite serious in elderly patients with multiple comorbid diseases. In addition, you should remember that taking NSAIDs and paracetamol can mask important symptoms of COVID-19 infection (in particular, fever) and lengthen the time for making a correct diagnosis.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>инфекция COVID-19</kwd><kwd>нестероидные противовоспалительные препараты</kwd><kwd>ибупрофен</kwd><kwd>парацетамол</kwd><kwd>острая респираторная вирусная инфекция</kwd><kwd>осложнения</kwd></kwd-group><kwd-group xml:lang="en"><kwd>COVID-19 infection</kwd><kwd>non-steroidal anti-inflammatory drugs</kwd><kwd>ibuprofen</kwd><kwd>paracetamol</kwd><kwd>acute respiratory viral diseases</kwd><kwd>complications</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Melville NA, Nainggolan L. Are Warnings Against NSAIDs in COVID-19 Warranted? Доступно по ссылке / Available at: https://www.medscape.com/viewarticle/926940</mixed-citation><mixed-citation xml:lang="en">Melville NA, Nainggolan L. Are Warnings Against NSAIDs in COVID-19 Warranted? Доступно по ссылке / Available at: https://www.medscape.com/viewarticle/926940</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Минздрав Франции: Ибупрофен может ухудшить состояние при коронавирусе. Доступно по ссылке: https://ren.tv/news/vmire/672805-minzdrav-frantsii-ibuprofen-mozhet-ukhudshit-sostoianie-pri-koronaviruse [French Ministry of Health: Ibuprofen may worsen the condition with coronavirus. Available at: https://ren.tv/news/vmire/672805-minzdrav-frantsii-ibuprofen-mozhet-ukhudshit-sostoianie-pri-koronaviruse (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Минздрав Франции: Ибупрофен может ухудшить состояние при коронавирусе. Доступно по ссылке: https://ren.tv/news/vmire/672805-minzdrav-frantsii-ibuprofen-mozhet-ukhudshit-sostoianie-pri-koronaviruse [French Ministry of Health: Ibuprofen may worsen the condition with coronavirus. Available at: https://ren.tv/news/vmire/672805-minzdrav-frantsii-ibuprofen-mozhet-ukhudshit-sostoianie-pri-koronaviruse (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Теслина А. ВОЗ рекомендовала не использовать ибупрофен для облегчения симптомов COVID-19. Доступно по ссылке: https://medvestnik.ru/content/news/VOZ-rekomendovala-neispolzovat-ibuprofen-dlya-oblegcheniya-simptomov-COVID- 19.html [Teslina A. WHO recommended not using ibuprofen to relieve the symptoms of COVID-19. Available at: https://medvestnik.ru/content/news/VOZ-rekomendovala-ne-ispolzovat-ibuprofen-dlyaoblegcheniya-simptomov-COVID-19.html (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Теслина А. ВОЗ рекомендовала не использовать ибупрофен для облегчения симптомов COVID-19. Доступно по ссылке: https://medvestnik.ru/content/news/VOZ-rekomendovala-neispolzovat-ibuprofen-dlya-oblegcheniya-simptomov-COVID- 19.html [Teslina A. WHO recommended not using ibuprofen to relieve the symptoms of COVID-19. Available at: https://medvestnik.ru/content/news/VOZ-rekomendovala-ne-ispolzovat-ibuprofen-dlyaoblegcheniya-simptomov-COVID-19.html (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ибупрофен или парацетамол? Ученые и врачи рассказали, что лучше принимать при COVID-19. Доступно по ссылке: https://medportal.ru/mednovosti/news/2020/03/18/055ibuprofen/ [Ibuprofen or paracetamol? Scientists and doctors have said that it is better to take with COVID-19. Available at: https://medportal.ru/mednovosti/news/2020/03/18/055ibuprofen/ (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Ибупрофен или парацетамол? Ученые и врачи рассказали, что лучше принимать при COVID-19. Доступно по ссылке: https://medportal.ru/mednovosti/news/2020/03/18/055ibuprofen/ [Ibuprofen or paracetamol? Scientists and doctors have said that it is better to take with COVID-19. Available at: https://medportal.ru/mednovosti/news/2020/03/18/055ibuprofen/ (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Доступно по ссылке: https://twitter.com/WHO/status/1240409217997189128 [Available at: https://twitter.com/WHO/status/1240409217997189128].</mixed-citation><mixed-citation xml:lang="en">Доступно по ссылке: https://twitter.com/WHO/status/1240409217997189128 [Available at: https://twitter.com/WHO/status/1240409217997189128].</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kim SY, Chang YJ, Cho HM, et al. Non-steroidal anti-inflammatory drugs for the common cold. Cochrane Database Syst Rev. 2015 Sep 21;(9):CD006362. doi: 10.1002/14651858.CD006362.pub4</mixed-citation><mixed-citation xml:lang="en">Kim SY, Chang YJ, Cho HM, et al. Non-steroidal anti-inflammatory drugs for the common cold. Cochrane Database Syst Rev. 2015 Sep 21;(9):CD006362. doi: 10.1002/14651858.CD006362.pub4</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Pierce CA, Voss B. Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review. Ann Pharmacother. 2010 Mar;44(3):489-506. doi: 10.1345/aph.1M332. Epub 2010 Feb 11.</mixed-citation><mixed-citation xml:lang="en">Pierce CA, Voss B. Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review. Ann Pharmacother. 2010 Mar;44(3):489-506. doi: 10.1345/aph.1M332. Epub 2010 Feb 11.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Wong T, Stang AS, Ganshorn H, et al. Combined and alternating paracetamol and ibuprofen therapy for febrile children. Cochrane Database Syst Rev. 2013 Oct 30;(10):CD009572. doi: 10.1002/14651858.CD009572.pub2</mixed-citation><mixed-citation xml:lang="en">Wong T, Stang AS, Ganshorn H, et al. Combined and alternating paracetamol and ibuprofen therapy for febrile children. Cochrane Database Syst Rev. 2013 Oct 30;(10):CD009572. doi: 10.1002/14651858.CD009572.pub2</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Jefferies S, Weatherall M, Young P, et al. The effect of antipyretic medications on mortality in critically ill patients with infection: a systematic review and meta-analysis. Crit Care Resusc. 2011 Jun;13(2):125-31.</mixed-citation><mixed-citation xml:lang="en">Jefferies S, Weatherall M, Young P, et al. The effect of antipyretic medications on mortality in critically ill patients with infection: a systematic review and meta-analysis. Crit Care Resusc. 2011 Jun;13(2):125-31.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Lee BH, Inui D, Suh GY, et al. Association of body temperature and antipyretic treatments with mortality of critically ill patients with and without sepsis: multi-centered prospective observational study. Crit Care. 2012 Feb 28;16(1):R33. doi: 10.1186/cc11211</mixed-citation><mixed-citation xml:lang="en">Lee BH, Inui D, Suh GY, et al. Association of body temperature and antipyretic treatments with mortality of critically ill patients with and without sepsis: multi-centered prospective observational study. Crit Care. 2012 Feb 28;16(1):R33. doi: 10.1186/cc11211</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Voiriot G, Philippot Q, Elabbadi A, et al. Risks Related to the Use of Non-Steroidal Anti-Inflammatory Drugs in CommunityAcquired Pneumonia in Adult and Pediatric Patients. J Clin Med. 2019 Jun 3;8(6). pii: E786. doi: 10.3390/jcm8060786</mixed-citation><mixed-citation xml:lang="en">Voiriot G, Philippot Q, Elabbadi A, et al. Risks Related to the Use of Non-Steroidal Anti-Inflammatory Drugs in CommunityAcquired Pneumonia in Adult and Pediatric Patients. J Clin Med. 2019 Jun 3;8(6). pii: E786. doi: 10.3390/jcm8060786</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Lanas A, McCarthy D, Voelker M, et al. Short-term acetylsalicylic acid (aspirin) use for pain, fever, or colds – gastrointestinal adverse effects: a meta-analysis of randomized clinical trials. Drugs R D. 2011 Sep 1;11(3):277-88. doi: 10.2165/11593880-000000000-00000</mixed-citation><mixed-citation xml:lang="en">Lanas A, McCarthy D, Voelker M, et al. Short-term acetylsalicylic acid (aspirin) use for pain, fever, or colds – gastrointestinal adverse effects: a meta-analysis of randomized clinical trials. Drugs R D. 2011 Sep 1;11(3):277-88. doi: 10.2165/11593880-000000000-00000</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Wen YC, Hsiao FY, Chan KA, et al. Acute Respiratory Infection and Use of Nonsteroidal Anti-Inflammatory Drugs on Risk of Acute Myocardial Infarction: A Nationwide Case-Crossover Study. J Infect Dis. 2017 Feb 15;215(4):503-9. doi: 10.1093/infdis/jiw603</mixed-citation><mixed-citation xml:lang="en">Wen YC, Hsiao FY, Chan KA, et al. Acute Respiratory Infection and Use of Nonsteroidal Anti-Inflammatory Drugs on Risk of Acute Myocardial Infarction: A Nationwide Case-Crossover Study. J Infect Dis. 2017 Feb 15;215(4):503-9. doi: 10.1093/infdis/jiw603</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Kellstein D, Fernandes L. Symptomatic treatment of dengue: should the NSAID contraindication be reconsidered? Postgrad Med. 2019 Mar;131(2):109-16. doi: 10.1080/00325481.2019.1561916. Epub 2019 Jan 16.</mixed-citation><mixed-citation xml:lang="en">Kellstein D, Fernandes L. Symptomatic treatment of dengue: should the NSAID contraindication be reconsidered? Postgrad Med. 2019 Mar;131(2):109-16. doi: 10.1080/00325481.2019.1561916. Epub 2019 Jan 16.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Доступно по ссылке / Available at: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30116-8/fulltext</mixed-citation><mixed-citation xml:lang="en">Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Доступно по ссылке / Available at: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30116-8/fulltext</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
